Hepatitis E in Transplantation

Current Infectious Disease Reports

Volumn 18, Issue 3, 2016, Pages 1-8

  Marion, Olivier ^a   Abravanel, Florence ^b,c   Lhomme, Sebastien ^b,c   Izopet, Jacques ^b,c   Kamar, Nassim ^a,b,c  

^a CHU RANGUEIL   (France)

^b CHU PURPAN   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Chronic hepatitis; Extra hepatic manifestations; Hepatitis E virus; Ribavirin; Transplantation

Indexed keywords

HEPATITIS E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; RIBAVIRIN; VIRUS RNA;

ACUTE HEPATITIS; ANTIBODY DETECTION; BLOOD TRANSFUSION; CLINICAL FEATURE; DISEASE COURSE; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; INCIDENCE; INFECTION PREVENTION; NONHUMAN; ORGAN TRANSPLANTATION; PREVALENCE; REVIEW; STEM CELL TRANSPLANTATION; VIRUS STRAIN; VIRUS TRANSMISSION;

EID: 84957538206     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-016-0515-z     Document Type: Review

References (88)

1. Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, et al. Hepatitis E. Lancet. 2012;379:2477–88. This is a comprehensive review summarizing current knowledge about hepatitis E virus.
2. Pavio N, Meng XJ, Doceul V. Zoonotic origin of hepatitis E. Curr Opin Virol. 2015;10:34–41. This is a comprehensive review summarizing the mode of transmission of hepatitis E virus.
3. Emerson SU, Nguyen HT, Torian U, Burke D, Engle R, Purcell RH. Release of genotype 1 hepatitis E virus from cultured hepatoma and polarized intestinal cells depends on open reading frame 3 protein and requires an intact PXXP motif. J Virol. 2010;84(18):9059–69.
4. Okamoto H, Takahashi M, Nishizawa T. Features of hepatitis E virus infection in Japan. Intern Med. 2003;42(11):1065–71.
5. Smith DB, Purdy MA, Simmonds P. Genetic variability and the classification of hepatitis e virus. J Virol. 2013;87(8):4161–9.
6. Lhomme S, Top S, Bertagnoli S, Dubois M, Guerin JL, Izopet J. Wildlife reservoir for hepatitis E virus, Southwestern France. Emerg Infect Dis. 2015;21(7):1224–6.
7. Mansuy JM, Saune K, Rech H, Abravanel F, Mengelle C, LH S, et al. Seroprevalence in blood donors reveals widespread, multi-source exposure to hepatitis E virus, southern France, October 2011. Euro Surveill. 2015;20(19):27–34.
8. Cook N, van der Poel WH. Survival and elimination of hepatitis E virus: a review. Food Environ Virol. 2015;7(3):189–94.
9. Abravanel F, Chapuy-Regaud S, Lhomme S, Miedouge M, Peron JM, Alric L, et al. Performance of anti-HEV assays for diagnosis acute hepatitis E in immunocompromised patients. J Clin Virol. 2013;58(4):624–8.
10. Abravanel F, Lhomme S, Chapuy-Regaud S, Peron JM, Alric L, Rostaing L, et al. Performance of a new rapid test for detecting anti-hepatitis E virus immunoglobulin M in immunocompetent and immunocompromised patients. J Clin Virol. 2015;70:101–4.
11. Bendall R, Ellis V, Ijaz S, Ali R, Dalton H. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol. 2010;82(5):799–805.
12. Mansuy JM, Bendall R, Legrand-Abravanel F, Saune K, Miedouge M, Ellis V, et al. Hepatitis E virus antibody in blood donors, France. Emerg Infect Dis. 2011;17(12):2309–12.
13. Baylis SA, Hanschmann KM, Blumel J, Nubling CM. Standardization of hepatitis E virus (HEV) nucleic acid amplification technique-based assays: an initial study to evaluate a panel of HEV strains and investigate laboratory performance. J Clin Microbiol. 2011;49(4):1234–9.
14. Abravanel F, Sandres-Saune K, Lhomme S, Dubois M, Mansuy JM, Izopet J. Genotype 3 diversity and quantification of hepatitis E virus RNA. J Clin Microbiol. 2012;50(3):897–902.
15. Kamar N, Rostaing L, Legrand-Abravanel F, Izopet J. How should hepatitis E virus infection be defined in organ-transplant recipients? Am J Transplant. 2013;13(7):1935–6.
16. Kamar N, Lhomme S, Abravanel F, Cointault O, Esposito L, Cardeau-Desangles I et al. An early viral response predicts the virological response to ribavirin in hepatitis E virus organ transplant patients. Transplantation. 2015
17. Abravanel F, Lhomme S, Rostaing L, Kamar N, Izopet J. Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse. Clin Infect Dis. 2015;60(1):96–9.
18. Hewitt PE, Ijaz S, Brailsford SR, Brett R, Dicks S, Haywood B, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet. 2014;384(9956):1766–73. In this original paper, the authors elegantly demonstrate the risk of transmission of hepatitis E virus by blood tranfusion.
19. Gallian P, Lhomme S, Piquet Y, Saune K, Abravanel F, Assal A, et al. Hepatitis E virus infections in blood donors, France. Emerg Infect Dis. 2014;20(11):1914–7.
20. Coilly A, Haim-Boukobza S, Roche B, Antonini TM, Pause A, Mokhtari C, et al. Posttransplantation hepatitis e: transfusion-transmitted hepatitis rising from the ashes. Transplantation. 2013;96(2):e4–6.
21. Schlosser B, Stein A, Neuhaus R, Pahl S, Ramez B, Kruger DH, et al. Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient. J Hepatol. 2012;56(2):500–2.
22. Abravanel F, Lhomme S, Chapuy-Regaud S, Mansuy JM, Muscari F, Sallusto F, et al. Hepatitis E virus reinfections in solid-organ-transplant recipients can evolve into chronic infections. J Infect Dis. 2014;209(12):1900–6.
23. Huang W, Zhang H, Harrison TJ, Lang S, Huang G, Wang Y. Cross-protection of hepatitis E virus genotypes 1 and 4 in rhesus macaques. J Med Virol. 2008;80(5):824–32.
24. Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis. 2008;8(11):698–709.
25. Kamar N, Garrouste C, Haagsma EB, Garrigue V, Pischke S, Chauvet C, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology. 2011;140(5):1481–9.
26. Dalton HR, Fellows HJ, Stableforth W, Joseph M, Thurairajah PH, Warshow U, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther. 2007;26(10):1429–35.
27. Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, Protiva P, Kleiner DE, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141(5):1665–72.
28. Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. Clin Microbiol Rev. 2014;27(1):116–38.
29. Dalton HR, Hazeldine S, Banks M, Ijaz S, Bendall R. Locally acquired hepatitis E in chronic liver disease. Lancet. 2007;369(9569):1260.
30. Peron JM, Bureau C, Poirson H, Mansuy JM, Alric L, Selves J, et al. Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy. J Viral Hepat. 2007;14(5):298–303.
31. Kamar N, Selves J, Mansuy JM, Ouezzani L, Peron JM, Guitard J, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358(8):811–7.
32. Dalton HR, Bendall R, Keane F, Tedder R, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med. 2009;361(10):1025–27.
33. le Coutre P, Meisel H, Hofmann J, Rocken C, Vuong GL, Neuburger S, et al. Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut. 2009;58(5):699–702.
34. Meisner S, Polywka S, Memmler M, Nashan B, Lohse AW, Sterneck M et al. Definition of chronic hepatitis E after liver transplant conforms to convention. Am J Transplant. 2015
35. Kamar N, Abravanel F, Selves J, Garrouste C, Esposito L, Lavayssiere L, et al. Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation. 2010;89(3):353–60.
36. Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2005;4:CD003961.
37. Wang Y, Zhou X, Debing Y, Chen K, Van der Laan LJ, Neyts J, et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology. 2014;146(7):1775–83.
38. Zhou X, Wang Y, Metselaar HJ, Janssen HL, Peppelenbosch MP, Pan Q. Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. J Hepatol. 2014
39. Suneetha PV, Pischke S, Schlaphoff V, Grabowski J, Fytili P, Gronert AA, et al. HEV-specific T-cell responses are associated with control of HEV infection. Hepatology Baltimore. MD. 2012;55(3):695–708.
40. Lhomme S, Abravanel F, Dubois M, Sandres Saune K, Rostaing L, Kamar N, et al. HEV quasispecies and the outcome of acute hepatitis E in solid-organ transplant patients. J Virol. 2012;86(18):100006–14.
41. Lhomme S, Garrouste C, Kamar N, Saune K, Abravanel F, Mansuy JM, et al. Influence of polyproline region and macro domain genetic heterogeneity on HEV persistence in immunocompromised patients. J Infect Dis. 2014;209(2):300–3.
42. Abravanel F, Mansuy JM, Huynh A, Kamar N, Alric L, Peron JM, et al. Low risk of hepatitis E virus reactivation after haematopoietic stem cell transplantation. J Clin Virol. 2012;54(2):152–5.
43. Knoenecke C, Pischke S, Heim A, Raggub L, Bremer B, Raupach R, et al. Chronic hepatitis E in hematopoietic stem cell transplant patients in low-endemic country. Transpl Infect Dis. 2012;14(1):103–6.
44. Versluis J, Pas SD, Agteresch HJ, de Man RA, Maaskant J, Schipper ME, et al. Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood. 2013;122(6):1079–86.
45. Koenecke C, Pischke S, Beutel G, Ritter U, Ganser A, Wedemeyer H, et al. Hepatitis E virus infection in a hematopoietic stem cell donor. Bone Marrow Transplant. 2014;49(1):159–60.
46. Tavitian S, Peron JM, Huynh A, Mansuy JM, Ysebaert L, Huguet F, et al. Hepatitis E virus excretion can be prolonged in patients with hematological malignancies. J Clin Virol. 2010;49(2):141–4.
47. Halac U, Beland K, Lapierre P, Patey N, Ward P, Brassard J, et al. Cirrhosis due to chronic hepatitis E infection in a child post-bone marrow transplant. J Pediatr. 2012;160(5):871–4.
48. Kamar N, Bendall RP, Peron JM, Cintas P, Prudhomme L, Mansuy JM, et al. Hepatitis E virus and neurologic disorders. Emerg Infect Dis. 2011;17(2):173–9.
49. van den Berg B, van der Eijk AA, Pas SD, Hunter JG, Madden RG, Tio-Gillen AP, et al. Guillain-Barre syndrome associated with preceding hepatitis E virus infection. Neurology. 2014;82(6):491–7. This is case-controlled study showing an association between hepatitis E virus and Guillain-Barré syndrome.
50. van Eijk JJ, Madden RG, van der Eijk AA, Hunter JG, Reimerink JH, Bendall RP, et al. Neuralgic amyotrophy and hepatitis E virus infection. Neurology. 2014;82(6):498–503. This is case-controlled study showing an association between hepatitis E virus and neuralgic amyotrophy.
51. Kamar N, Izopet J, Cintas P, Garrouste C, Uro-Coste E, Cointault O, et al. Hepatitis E virus-induced neurological symptoms in a kidney-transplant patient with chronic hepatitis. Am J Transplant. 2010;10(5):1321–4.
52. Kamar N, Mansuy JM, Esposito L, Legrand-Abravanel F, Peron JM, Durand D, et al. Acute hepatitis and renal function impairment related to infection by hepatitis E virus in a renal allograft recipient. Am J Kidney Dis. 2005;45(1):193–6.
53. Kamar N, Weclawiack H, Guilbeaud-Frugier C, Legrand-Abravanel F, Cointault O, Ribes D, et al. Hepatitis E virus and the kidney in solid-organ-transplant patients. Transplantation. 2012;93(6):617–23.
54. Taton B, Moreau K, Lepreux S, Bachelet T, Trimoulet P, De Ledinghen V, et al. Hepatitis E virus infection as a new probable cause of de novo membranous nephropathy after kidney transplantation. Transpl Infect Dis. 2013;15(6):E211–5.
55. Del Bello A, Guilbeau-Frugier C, Josse AG, Rostaing L, Izopet J, Kamar N. Successful treatment of hepatitis E virus-associated cryoglobulinemic membranoproliferative glomerulonephritis with ribavirin. Transpl Infect Dis. 2015;17(2):279–83.
56. Pischke S, Behrendt P, Manns MP, Wedemeyer H. HEV-associated cryoglobulinaemia and extrahepatic manifestations of hepatitis E. Lancet Infect Dis. 2014;14(8):678–9.
57. Pischke S, Polywka S, Haag F, Iking-Konert C, Sterneck M, Lutgehetmann M, et al. Association of hepatitis E virus and essential cryoglobulinemia? J Clin Virol. 2015;67:23–4.
58. Kamar N, Rostaing L, Abravanel F, Garrouste C, Esposito L, Cardeau-Desangles I, et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis. 2010;50(5):e30–3.
59. Kamar N, Abravanel F, Garrouste C, Cardeau-Desangles I, Mansuy JM, Weclawiak H, et al. Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. Nephrol Dial Transplant. 2010;25(8):2792–5.
60. Haagsma EB, Riezebos-Brilman A, van den Berg AP, Porte RJ, Niesters HG. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transpl. 2010;16(4):474–7.
61. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation. 1995;59(10):1426–31.
62. Mallet V, Nicand E, Sultanik P, Chakvetadze C, Tesse S, Thervet E, et al. Brief communication: case reports of ribavirin treatment for chronic hepatitis E. Ann Intern Med. 2010;153(2):85–9.
63. Kamar N, Rostaing L, Abravanel F, Garrouste C, Lhomme S, Esposito L, et al. Ribavirin therapy inhibits viral replication in patients with chronic hepatitis E virus infection. Gastroenterology. 2010;139(5):1612–8.
64. Pischke S, Hardkte S, Bode U, Birkner S, Chatzikyrkou C, Kauffmann W, et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int. 2013;33(5):722–6.
65. Kamar N, Izopet J, Tripon S, Bismuth M, Hillaire S, Dumortier J, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med. 2014;370(12):1111–20. It is a retrospective multicenter study that showed that ribavirin monotherapy is highly efficient for treating hepatitis E virus infection.
66. Debing Y, Gisa A, Dallmeier K, Pischke S, Bremer B. Manns M et al. Gastroenterology: A Mutation in the Hepatitis E Virus RNA Polymerase Promotes its Replication and Associates with Ribavirin Treatment Failure in Organ Transplant Recipients; 2014.
67. Debing Y, Emerson SU, Wang Y, Pan Q, Balzarini J, Dallmeier K, et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrob Agents Chemother. 2014;58(1):267–73.
68. Kamar N, Mallet V, Izopet J. Ribavirin for chronic hepatitis E virus infection. N Engl J Med. 2014;370(25):2447–8.
69. Kamar N, Izopet J, Rostaing L. No reactivation of hepatitis E virus after kidney retransplantation. Am J Transplant. 2012;12(2):507–8.
70. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010;376(9744):895–902.
71. Zhang J, Zhang XF, Huang SJ, Wu T, Hu YM, Wang ZZ, et al. Long-term efficacy of a hepatitis E vaccine. N Engl J Med. 2015;372(10):914–22. This paper confirms the long-term efficacy of the Chinese hepatitis E virus vaccine.
72. Legrand-Abravanel F, Kamar N, Sandres-Saune K, Lhomme S, Mansuy JM, Muscari F, et al. Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France. Emerg Infect Dis. 2011;17(1):30–7.
73. Legrand-Abravanel F, Kamar N, Sandres-Saune K, Garrouste C, Dubois M, Mansuy JM, et al. Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis. 2010;202(6):835–44.
74. Buffaz C, Scholtes C, Dron AG, Chevallier-Queyron P, Ritter J, Andre P, et al. Hepatitis E in liver transplant recipients in the Rhone-Alpes region in France. Eur J Clin Microbiol Infect Dis. 2014;33(6):1037–43.
75. Buti M, Cabrera C, Jardi R, Castells L, Esteban R. Are recipients of solid organ transplantation a high-risk population for hepatitis E virus infection? Liver Transpl. 2010;16(1):106–7.
76. Haagsma EB, Niesters HG, van den Berg AP, Riezebos-Brilman A, Porte RJ, Vennema H, et al. Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl. 2009;15(10):1225–8.
77. Koning L, Charlton MR, Pas SD, Heimbach JK, Osterhaus AD, Watt KD, et al. Prevalence and clinical consequences of hepatitis E in patients who underwent liver transplantation for chronic hepatitis C in the United States. BMC Infect Dis. 2015;15(1):371.
78. Laverdure N, Scholtes-Brunel C, Rivet C, Heissat S, Restier L, Bacchetta J, et al. Paediatric liver transplanted patients and prevalence of hepatitis E virus. J Clin Virol. 2015;69:22–6.
79. Moal V, Legris T, Burtey S, Morange S, Purgus R, Dussol B, et al. Infection with hepatitis E virus in kidney transplant recipients in southeastern France. J Med Virol. 2012;85(3):462–71.
80. Moal V, Legris T, Motte A, Vacher-Coponat H, Fages L, Jourde-Chiche N, et al. Systematic serological testing for hepatitis E virus in kidney transplant recipients. J Clin Microbiol. 2015;53(5):1523–30.
81. Magnusson J, Norder H, Riise GC, Andersson LM, Brittain-Long R, Westin J. Incidence of hepatitis E antibodies in Swedish lung transplant recipients. Transplant Proc. 2015;47(6):1972–6.
82. Naik A, Gupta N, Goel D, Ippagunta SK, Sharma RK, Aggarwal R. Lack of evidence of hepatitis E virus infection among renal transplant recipients in a disease-endemic area. J Viral Hepat. 2013;20(4):e138–40.
83. Pas SD, de Man RA, Mulders C, Balk AH, van Hal PT, Weimar W, et al. Hepatitis E virus infection among solid organ transplant recipients, the Netherlands. Emerg Infect Dis. 2012;18(5):869–72.
84. Pischke S, Suneetha PV, Baechlein C, Barg-Hock H, Heim A, Kamar N, et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl. 2010;16(1):74–82.
85. Pischke S, Stiefel P, Franz B, Bremer B, Suneetha PV, Heim A, et al. Chronic hepatitis E in heart transplant recipients. Am J Transplant. 2012;12(11):3128–33.
86. Pischke S, Greer M, Hardtke S, Bremer B, Gisa A, Lehmann P, et al. Course and treatment of chronic hepatitis E virus infection in lung transplant recipients. Transpl Infect Dis. 2014;16(2):333–9.
87. Riezebos-Brilman A, Puchhammer-Stöckl E, Van der Weide H, Haagsma EB, Jaksch P, Bejvl I, et al. Chronic hepatitis E infection in lung transplant recipients. J Heart Lung Transplant. 2013;32(3):341–6.
88. Sherman KE, Terrault N, Barin B, Rouster SD, Shata MT, Investigators H-T. Hepatitis E infection in HIV-infected liver and kidney transplant candidates. J Viral Hepat. 2014;21(8):e74–7.